Introduction: The Intersection of Precision Radiotherapy and Biological Agents
In the rapidly evolving landscape of modern oncology, the management of metastatic and oligometastatic disease has shifted from purely palliative intent to more aggressive, multi-modality approaches aimed at prolonging survival and improving quality of life. At the forefront of this shift are two powerful pillars: metastases-directed stereotactic radiotherapy (SRT) and biological cancer therapy (BCT), including immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), and small-molecule drugs (SMs). While each modality has revolutionized patient outcomes independently, their combination raises critical questions regarding safety and potential toxic synergy. The findings from the TOaSTT (Toxicity and Efficacy of Combined Stereotactic Radiotherapy and Systemic Targeted or Immune Therapy) registry, recently published in JAMA Network Open, provide much-needed prospective evidence to guide clinicians in these complex decision-making processes.
Background: Addressing the Knowledge Gap in Combined Modalities
For years, clinicians have operated in a state of clinical uncertainty when patients receiving biological agents required radiotherapy for metastatic lesions. The primary concern has been the potential for ‘radiosensitization’ of healthy tissues—where biological agents might exacerbate radiation-induced inflammation or where radiation might trigger systemic immune-related adverse events (irAEs). Historically, many protocols suggested pausing systemic therapy during radiation to mitigate these risks. However, such interruptions carry their own dangers, potentially allowing for systemic disease escape or the loss of therapeutic momentum.
Despite the increasing frequency of this combined approach, high-quality, prospective data on the incidence of severe adverse events have been sparse. Most existing literature consists of retrospective case series or small, single-center cohorts. The TOaSTT study was designed to address this unmet medical need by prospectively monitoring patients across multiple international centers to establish a definitive safety profile for concurrent SRT and BCT.
The TOaSTT Registry: Study Design and Methodology
Patient Population and Exposure Parameters
The TOaSTT study was an international, prospective, multicenter, noninterventional registry cohort study conducted between July 2017 and August 2019. The study enrolled 433 patients across 27 centers. These patients underwent a total of 514 SRT procedures (271 cranial and 243 extracranial) while receiving concurrent BCT. Concurrence was strictly defined as BCT administration within 30 days of the SRT procedure.
The cohort was predominantly male (63.5%) with a median age of 62 years. The biological therapies used were diverse, reflecting current clinical practice: 61.3% of treatments involved ICIs, 29.2% involved small-molecule inhibitors (SMs), and 9.5% involved monoclonal antibodies (mAbs). Interestingly, the study captured real-world clinical decision-making, as the choice of radiotherapy dose, fractionation, and whether to pause BCT was left to the discretion of the treating physician.
Outcome Measures
The primary endpoint of the study was the incidence of severe adverse events, defined as Grade 3 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE). These were further categorized into acute events (occurring during or shortly after treatment) and late events (identified during the 24-month follow-up period). Secondary endpoints included progression-free survival (PFS) and overall survival (OS), providing a holistic view of the treatment’s impact.
Key Findings: Safety and Efficacy Outcomes
Incidence of Severe Adverse Events
The core finding of the TOaSTT registry is the remarkably low incidence of severe toxicity. Severe (Grade 3 or higher) acute adverse events were observed in only 5.3% of treatments (27 of 506). This included three instances of Grade 5 (fatal) events, which are always a concern in advanced cancer populations but must be viewed in the context of the overall cohort’s disease burden. Severe late adverse events were similarly infrequent, occurring in 6.3% of patients (29 of 459), with two Grade 5 events reported.
These rates are comparable to, and in some cases lower than, those reported for systemic therapy or radiotherapy alone in similar metastatic populations. This suggests that the combination does not result in a cumulative toxicity profile that exceeds the safety threshold for standard clinical practice.
The Impact of Therapy Interruption
One of the most clinically relevant questions addressed by the study was whether pausing biological therapy during radiation improved safety. The data suggests it does not. In 83.7% of cases, BCT had been initiated before SRT. Approximately 18.1% of patients paused their BCT during the SRT course. Statistical analysis revealed that continuing BCT without interruption was not associated with an increased risk of severe acute or late adverse events (Odds Ratio [OR], 2.32; 95% CI, 0.87-6.22). While the point estimate for the OR might appear elevated, the wide confidence interval crossing 1.0 indicates a lack of statistical significance, suggesting that physician selection bias—where healthier patients were more likely to continue therapy—may play a role, but the overall safety remained manageable.
Survival and Disease Progression
Beyond safety, the study looked at whether interrupting BCT impacted the efficacy of the cancer treatment. After correcting for performance status and histologic type, the researchers found that interrupting BCT during SRT was not associated with worse PFS or OS (Hazard Ratio [HR], 0.81; 95% CI, 0.61-1.09; P = .17). This finding is vital for clinicians who may feel compelled to pause systemic treatment due to fear of toxicity; while pausing may not necessarily harm survival in the short term, it also does not appear to provide a safety benefit that justifies the interruption.
Clinical Implications and Expert Interpretation
Biological Plausibility and Interaction Management
The lack of significant interaction between SRT and BCT observed in this study supports the prevailing theory that modern, highly targeted radiotherapy minimizes the ‘bystander’ effect on healthy tissue, even when the immune system is primed by ICIs. From a mechanistic standpoint, radiation is known to release tumor-associated antigens and promote a pro-inflammatory microenvironment, which theoretically enhances the efficacy of ICIs—a phenomenon known as the abscopal effect. The TOaSTT data suggests that this immunomodulatory synergy can be achieved without triggering a corresponding surge in systemic toxicity.
For small-molecule drugs and monoclonal antibodies, which often target specific signaling pathways (e.g., EGFR, VEGF, or HER2), the study confirms that the localized nature of SRT does not typically lead to catastrophic systemic failures or unexpected localized tissue breakdown when these agents are circulating.
Limitations and Future Directions
While the TOaSTT registry provides robust prospective data, it is important to acknowledge its noninterventional nature. The ‘discretion of the treating clinician’ introduces a degree of selection bias. For example, clinicians might have been more likely to pause BCT in patients they perceived as being at higher risk for complications. Furthermore, while the overall sample size is large, the diversity of BCT agents means that specific drug-radiation interactions (e.g., a specific TKI combined with liver SRT) may still require more granular investigation.
Future research should focus on randomized controlled trials that specifically compare continuous versus interrupted therapy to eliminate selection bias. Additionally, identifying biomarkers that predict which patients might be at higher risk for combined-modality toxicity remains a priority for personalized oncology.
Conclusion: A Shift Towards Continuous Integration
The TOaSTT registry provides a reassuring evidence base for the concurrent use of stereotactic radiotherapy and biological cancer therapies. With severe adverse events occurring in fewer than 10% of patients and no clear evidence that interrupting systemic therapy improves safety, the study supports the trend toward continuous, integrated treatment for metastatic disease. For clinicians, these findings suggest that SRT can be safely integrated into the biological treatment journey, allowing for local control of symptomatic or progressing metastases without necessitating a detour from systemic therapeutic goals.
Funding and ClinicalTrials.gov
This study was supported by various institutional grants and the participating centers of the TOaSTT registry. ClinicalTrials.gov Identifier: NCT03185312.
References
1. Looman EL, Kroeze SGC, Schaule J, et al. Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy. JAMA Netw Open. 2026;9(1):e2553809. doi:10.1001/jamanetworkopen.2025.53809
2. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051-2058.
3. Herrera FG, Bourhis J, Coukos G. Radiotherapy combined with checkpoint inhibition (RICI): generalized concept and mechanisms of action. Ann Oncol. 2017;28(1):45-55.